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A B S T R A C T 
Introduction: Cisplatin is a commonly prescribed drug that produces ototoxicity as a 
side effect. Lutein is a carotenoid with antioxidant and anti-inflammatory properties 
previously tested for eye, heart and skin diseases but not evaluated to date in ear 
diseases. 
Aim: To evaluate the protective effects of lutein on HEI-OC1 auditory cell line and in a 
Wistar rat model of cisplatin ototoxicity. 
Materials and Methods: In vitro study: Culture HEI-OC1 cells were exposed to lutein 
(2.5–100 mM) and to 25 mM cisplatin for 24 h. In vivo study: Twenty eight female 
Wistar rats were randomized into three groups. Group A (n = 8) received intratympanic 
lutein (0.03 mL) (1 mg/mL) in the right ear and saline solution in the left one to 
determine the toxicity of lutein. Group B (n = 8) received also intraperitoneal cisplatin 
(10 mg/kg) to test the efficacy of lutein against cisplatin ototoxicity. Group C (n = 12) 
received intratympanic lutein (0.03 mL) (1 mg/mL) to quantify lutein in cochlear fluids 
(30 min,1 h and 5 days after treatment). Hearing function was evaluated by means of 
Auditory Steady-State Responses before the procedure and 5 days after (groups A and 
B). Morphological changes were studied by confocal laser scanning microscopy. 
Results: In vitro study: Lutein significantly reduced the cisplatin-induced cytotoxicity in 
the HEI-OC1 cells when they were pre-treated with lutein concentrations of 60 and 80 
mM. In vivo study: Intratympaniclutein (1 mg/mL) application showed no ototoxic 
effects. However it did not achieve protective effect against cisplatin-induced 
ototoxicity in Wistar rats. 
Conclusions: Although lutein has shown beneficial effects in other pathologies, the 
present study only obtained protection against cisplatin ototoxicity in culture cells, but 
not in the in vivo model. The large molecule size, the low dose administered, and 
restriction to diffusion in the inner ear could account for this negative result 
1. Introduction 
Cisplatin is a commonly prescribed platinum-based drug used to treat various types of 
solid tumors (testicular and ovarian carcinoma, squamous head and neck carcinoma, 
advanced bladder cancer, lung carcinoma, malignant gliomas and metastatic cancers 
such as melanoma, mesothelioma, prostate and breast cancer). 
Severe side effects such as ototoxicity, nephrotoxicity, myelotoxicity and 
gastrointestinal toxicity have been reported due to cisplatin treatment. Although 
nephrotoxicity can be diminished or controlled with hydration therapy, ototoxicity still 
poses a limitation to effective cisplatin chemotherapy (McKeage, 1995). There is a 
great interest in developing effective strategies to protect the inner ear without 
compromising the antitumoral activity of cisplatin. Unfortunately, no therapy is 
currently approved for clinical use. Histologically, cisplatin causes cell death by 
apoptosis through different intracellular pathways. One of them is the overproduction 
of reactive oxygen species (ROS). This increase of ROS activate the cell compensation 
mechanisms, releasing glutathione enzymes and antioxidant substances. 
Antioxidant system depletion leads to cell apoptosis. Many experimental studies have 
attempted to evaluate different substances against ROS overload and other cell 
signaling systems at an early stage to stop the apoptotic pathways. There is a clear 
rationale behind the testing of antioxidants against cisplatin ototoxicity as the overload 
of ROS after cisplatin administration has been shown to be one of the main 
mechanisms triggering death pathways inside auditory sensory cells (Casares et al., 
2012). 
Lutein is part of the xanthophylls chemical group. It is the second carotenoid most 
frequently found in human serum (Khachik et al., 1997), and it is present in foods such 
as corn, papaya, dairy, cereal, citrus fruits and green leafy vegetables such as spinach 
and kale (Sommerburg et al., 1998). The molecular structure of lutein has two hydroxyl 
groups, one at each end of the molecule, essential for its biological action as an 
antioxidant (Johnson, 2002; Winkler et al., 1999). There have been many studies on 
the benefits of lutein in humans due to its antioxidant properties. Most of them deal 
with the potential protective action of lutein in eye diseases (Landrum and Bone, 2001; 
Beatty et al., 1999; Duncan et al., 2002), and also in heart (Howard et al., 1996; 
Krieglstein and Granger, 2001; Martin et al., 2000) and skin diseases (Alves Rodrigues 
and Shao, 2004; Britton, 1995; Krinsky, 2002; Dreher and Maibach, 2001). Recent 
studies suggest a protective effect against neurodegenerative disorders such as 
Alzheimer’s and Parkinson’s diseases (Min and Min, 2014; Nataraj et al., 2015). 
Up to the date there are no reports evaluating the effect of lutein on the inner ear. 
Due to the common characteristics between the inner ear and the retina, the 
antioxidant property of lutein, and the role of ROS overload in cisplatin ototoxicity, we 
hypothesized that lutein might play a role as a protective agent against cisplatin 
ototoxicity. 
The aim of the present study was to evaluate the potential protective effect of lutein 
against cisplatin-initiated damage to the cochlea both in vitro and in vivo. 
2. Materials and methods 
2.1. In vitro study 
2.1.1. Chemicals 
Cisplatin (1 mg/mL) was purchased from Accord Healthcare (Barcelona, Spain). 
Lutein (Xanthophyll from Marigold) was purchased from Sigma–Aldrich (Sigma–
Aldrich; St. Louis, USA). Lutein is a very lipophilic carotenoid, so it was diluted in 0.5% 
DMSO in a phosphate buffered saline solution (PBS, Sigma–Aldrich, Germany) and 
different dilutions were prepared from stock solution. DMSO (Dimethyl sulfoxide) 
(0.5%) was purchased from Sigma–Aldrich (Sigma–Aldrich; St. Louis, USA). 
2.1.2. Cell culture 
The House Ear Institute-Organ of Corti 1 (HEI-OC1) cell line was kindly provided by Dr. 
Federico Kalinec (House Ear Institute, Los Angeles, CA). The establishment and 
characterisation of the conditionally immortalised HEI-OC1 cell line were previously 
described by Kalinec et al. (2003). 
HEI-OC1 cells were maintained in high-glucose Dulbecco’s modified Eagle’s medium 
(DMEM; Sigma, Saint Louis, MO, USA) supplemented with 10% fetal bovine serum 
(FBS; Gibco, BRL), 5% LGlutamine (Sigma, Saint Louis, MO, USA) and Penicillin-G 
(Sigma, Saint Louis, MO, USA) at 33 C in a humidified incubator with 10% CO2. 
For the experiments described below, HEI-OC1 cells were cultured under permissive 
conditions: 33 C, 5% CO2 in DMEM supplemented with 10% FBS  
2.1.3. Cell viability assay AlamarBlue1 (Invitrogen) is a proven cell viability indicator 
that uses the natural reducing power of living cells to convert resazurin to the 
fluorescent molecule, resorufin. The active ingredient, resazurin, is a nontoxic, cell 
permeable compound that is blue in color and virtually nonfluorescent. Upon entering 
cells, resazurin is reduced to resorufin, which produces very bright red fluorescence. 
Viable cells continuously convert resazurin to resorufin, thereby generating a 
quantitative measure of viability and cytotoxicity. Absorbances at 570 nm were 
measured on a Multi-Detection Microplate Reader Synergy HT (BioTek Instru-ments; 
Vermont, USA). The treatments were performed in replicates (eight wells per treatment 
in a microplate). Results of the experiments are expressed as a percentage of viable cells 
(% of viable cells).  
2.1.4. Hoechst 33258 staining Apoptotic cell death was determined by evaluating the 
nuclear morphology using Hoechst 33258 staining. Cells were incubated with 10 
mg/mL of Hoechst 33258 (Sigma, Saint Louis, MO, USA) for 20 min. Membrane-
permeable Hoechst 33258 is a blue fluorescent dye and stained the cell nucleus. After 
washing twice with phosphate buffered saline (PBS), the cells were fixed with 4% 
paraformaldehyde for 10 min at room temperature (RT). After washing twice with 
distilled water, the cells were evaluated under a Nikon Eclipse TE 2000-S fluorescence 
microscope with a DS-U2 camera controller (Nikon Instruments Europe BV, 
Amsterdam, Netherlands).  
2.1.5. Lutein toxicity assay HEI-OC1 cells were seeded in 96-well plates, with each well 
containing 3  _104 cells. After 24 h incubation under permissive conditions (33  _C, 
10% CO2 in DMEM), the cells were treated with various lutein dilutions (2.5, 5, 10, 20, 
30, 40, 60, 80 or 100 mM) and viability assessed after 24 h.  
2.1.6. Cisplatin toxicity assay Cells were treated with various cisplatin dilutions (0.625, 
1.25, 2.5, 5, 10, 20, 30, 40 or 60 mM) and viability assessed after 24 h. A concentration 
of 25 mM was the half-maximal inhibitory concen-tration (IC50) for 24 h in DMEM.  
2.1.7. Lutein effects against cisplatin toxicity HEI-OC1 cells were seeded as previously 
described. Cisplatin was added 3 h after lutein administration to allow for carotenoid's 
endocytosis by cells. Cells were exposed to 25 mM cisplatin (IC50).  
2.1.8. Statistical analysis A statistitical analyse was performed to determine the sample 
size for each group. The experiment was performed twice at different times, with eight 
repetitions for each dilution used. Analysis of variance was used to assess mean 
differences across treatment groups. One-way ANOVA was used to assess statistical 
significance, where values of p < 0.05 were considered statistically significant. A Tukey 
test was used to identify significant differences between the paired treatments. Data 
processing and analysis were performed with Origin Pro 8 software package (Origin 
Lab Corporation, Northampton, USA).  
2.2. In vivo study The study was carried out in compliance with guidelines for research 
involving animals (Spanish Animal Care and Use Committee, Spanish Law 32/2007 
and EU Directive 2010/63/EU for animal experiments), and was approved by the 
Animal Welfare Ethics Committee of the Foundation for Biomedical Research of 
Puerta de Hierro Hospital (CEBA 013/2012).  
2.2.1. Animals Female Wistar rats weighing 250–275 g were used. Animals were bred 
and handled at the animal facilities of our centre in temperature controlled rooms, 
with light–dark cycles, and with free access to food and water. Before each procedure, 
an otoscopy was performed on each animal to exclude outer and middle ear 
infections, using an operating microscope. Rats showing signs of current or past middle 
ear infection were excluded from this study.  
2.2.2. Experimental groups Twenty eight animals were randomly assigned to three 
groups: Group A (n = 8) received intratympanic lutein (0.03 mL) (1 mg/mL) in the right 
ear (0.03 mL) and saline solution in the left ear (0.03 mL), to determine the toxicity of 
lutein. Group B (n = 8) received intratympanic lutein (0.03 mL) in the right ear, saline 
solution (0.03 mL) in the left ear and intraperito- neal cisplatin (10 mg/kg), to test the 
efficacy of lutein against cisplatin ototoxicity. Group C (n = 12) received intratympanic 
lutein (0.03 mL) (1 mg/mL) in the right ear. Animals were euthanised and cochlear fluid 
sampled 30 minutes (n = 4), 1 h (n = 4) and 5 days (n = 4) after lutein administration, to 
measure the diffusion of lutein from middle to inner ear.  
2.2.3. Study design Animals were anaesthetised with intraperitoneal ketamine (100 
mg/kg) and diazepam (0.1 mg/kg). Pretreatment Auditory Steady-State Responses 
(ASSR) were obtained from the animals in groups A and B. Following the ASSR 
measurements, lutein and saline solution were injected intratympanically using a 
spinal needle (BD Whitecare 27G). After lutein injection, the animals remained in 
lateral decubitus for 30 min to maximize the time of contact between the solution and 
the round window membrane, and to prevent its leakage into the pharynx through the 
Eustachian tube. This procedure was performed in both groups. After intratympanic 
injection, animals from group B received treatment with cisplatin through a slow 
intraperitoneal infusion during 30 min. Animals were housed in individual cages with 
ad libitum water and food. Five days after treatment a new ASSR evaluation was 
performed. The threshold auditory levels were compared with pretreatment values. 
Animals were euthanised by decapitation after CO suffocation. Temporal bones were 
obtained for histological study in groups A and B and for perilymphatic fluid sampling 
in group C.  
2.2.4. Lutein preparation Lutein was diluted in 0.5% DMSO with PBS. DMSO was chosen 
as the solvent for its ability to increase the round window membrane permeability. 
Moreover, a previous study from our group showed that intratympanic 0.5% DMSO 
was not intrinsically ototoxic and did not increase the ototoxic effect of cisplatin 
(Roldán-Fidalgo et al., 2014).  
2.2.5. Auditory steady-state responses Subcutaneous electrodes were placed over the 
vertex (active) and in the pinna of each ear (reference). An insert earphone (Etymotic 
ER-2) was placed directly into the external auditory canal. Ground electrodes were 
placed over the neck muscles. ASSR were recorded using an evoked potential 
averaging system (Intelligent Hearing System Smart-EP, FL, USA) in an electrically 
shielded, double-walled, sound-treated booth in response to 100 ms clicks or tone 
bursts, at 8, 12, 16, 20, 24 and 32 kHz with 10 ms plateau and 1 ms rise/fall time. 
Intensity was expressed in decibels sound pressure level (dB SPL) peak equivalent. 
Intensity series were recorded, and an ASSR threshold was defined by the lowest 
intensity able to induce a replicable visual detectable response.  
2.2.6. Histology The cochlear portion of the temporal bone was isolated. The stape 
was removed and the round window membrane carefully incised, in order to perfuse 
glutaraldehyde through the round window to rinse the endolymphatic and 
perilymphatic spaces. The piece was fixed in glutaraldehyde for 24 h and decalcified in 
1% ethylenediaminetetraacetic acid (EDTA) at room temperature for 10–12 days, with 
daily changes. Cochleae were dissected in PBS medium and cochlear surface extracts 
were laid for confocal microscopy analysis (Leica TCS SP5 with a 63 _ objective). The 
total number of outer hair cells (OHC) and the OHC loss (considered by the presence of 
empty spaces in OHC rows) were reported for each extract. Cell counts were 
performed at the time of imaging by sequentially viewing each slice.  
2.2.7. Lutein quantification In group C, after the removal of the temporal bone and 
isolation of the cochlear portion, the bony apex of the cochlea was removed with a 
needle. The tip of a 50 mL Hamilton pipette was adjusted to the cochlear apical 
opening and the perilymphatic fluid suctioned with a syringe pump. All the samples 
were stored at  _80  _C until analysis. The presence of lutein in the sampled fluid was 
analysed using high performance liquid chromatography (HPLC). Lutein was analyzed 
with high performance liquid chromatog- raphy (HPLC) using a system consisting of a 
model 600 pump, a Rheodyne injector and a 2998 photodiode array (PDA) detector 
(Waters, Milford, MA, USA) following standard procedures previously defined 
(Olmedilla et al., 2001) a Spheri-5-ODS column (220 mm  _ 4.6 mm) (Brownlee Labs, 
Applied Biosystems, Santa Clara, CA, USA) and a guard column (ODS Aquapore type RP-
18). The mobile phase was acetonitrile-methanol (85:15; v/v), and was changed to 
acetonitrile-dichloromethanemethanol (70:20:10; v/v/v) in a linear gradient from min 
5 to min 20. Both mobile phases were stabilised with ammonium acetate (0.025 mol/L) 
added to the methanol. The flow rate was 1.8 mL/min, and detection was performed 
at a wavelength of 450 nm. All chromato- grams were processed using Empower 2 
software (Waters, Milford, MA, USA). Lutein extraction was performed on perilymph 
samples as follows: Centrifugation of the sample to concentrate the liquid at the 
bottom of the Eppendorf pellet (1 min). 300 mL of water, 30 mL of ethanol (EtOH) and 
60 mL of hexane was added. Vortex was performed during 1 min. Centrifugation of the 
sample during 5 min at 3500 rpm. The supernatant was collected and dried under 
nitrogen and reconstituted with 25 ml of EtOH and tetrahydrofuran (THF) (2:1). The 
mixture was then stirred under ultrasound. Injection of the entire volume into the 
HPLC. The concentration of lutein was 0.27–1.36 mg/ mL(R2 = 0.999), folowing a 
normal distribution curve. 
2.2.8. Statistical analysis All statistical analyses were carried out using the SPSS 
statistical software package (SPSS, version 16.0 for windows; SPSS Inc., Chicago, IL, 
USA). Comparison between the groups with ASSR thresholds was performed using 
one-way and two-way analysis of variance (ANOVA). T-tests for paired samples were 
used to compare the ASSR thresholds, before and after lutein administra- tion in 
groups A and B. Values of p < 0.05 were considered statistically significant. 
3. Results  
3.1. In vitro study  
3.1.1. Toxicity assays Cell cultures treated with lutein alone showed no significant cell 
damage or cell loss (Fig. 1A). A clear dose effect was observed. Low carotenoid 
concentration did not affect cell viability, but exposure to concentrations of 60 and 80 
mM produced a significant reduction on cell viability (81% and 84% respectively). The 
HEI-OC1 cell line treated with cisplatin showed statistically significant cell damage 
(Fig. 1B). Changes to the pro-apoptotic nuclei were observed after Hoechst 33258 
staining. Higher doses of cisplatin decreased survival of the cells in a dose-dependent 
manner. After exposure of the cells to cisplatin, the cellular viability was reduced from 
10 mM to higher concentrations. Concentrations ranging from 20 mM to 60 mM are 
cytotoxic, since they decrease cell viability over 70% (as determined by ISO 10993- 
5:2009) (Fig. 1B, discontinued line). For this reason, a 25 mM cisplatin concentration 
was chosen as an adequate dose to test the protective effect of lutein against 
antitumoral toxicity.  
3.1.2. Lutein effect against cisplatin ototoxicity A cytoprotective effect was observed in 
HEI-OC1 cells exposed to cisplatin after pretreatment with lutein. A statistically signifi-
cant increase in cell viability was seen after pretreatment with lutein at concentrations 
of 60 mM and 80 mM (Fig. 2A). Cell viability as a percentage of the control group was 
84% and 81%, respectively (p < 0.05). Lower concentrations of lutein were not able to 
prevent cell death. Concentrations below 60 mM failed to antagonize the harmful 
effect of the ROS overproduction after cisplatin treatment. Cytotoxic concentrations of 
lutein (100 mM) did not show any protection against cisplatin. Due to the high 
molecular weight of lutein, the use of high concentrations could induce lutein 
precipitation within the inner ear cells and limit its protective effect. Apoptosis of HEI-
OC1 cells induced by cisplatin was also evaluated by nuclear Hoechst 33258 staining 
after 24 h treatment (Fig. 2B, C and D). Cells treated with cisplatin alone showed 
decreased survival and exhibited apoptotic nuclei (Fig. 2B). When cells received 80 mM 
lutein (Fig. 2C), cell viability was preserved when compared to the control group (p < 
0.05) (Fig. 2D). 
3.2. In vivo study  
3.2.1. Group A Post-treatment ASSR recordings were found to be lower thanpre- 
treatment ASSR recordings, both in the study ear (lutein) and the control ear (saline 
solution), but the differences were not statistically significant for any of the tested 
frequencies (Fig. 3). These findings suggest that lutein is not intrinsically ototoxic for 
the inner ear when applied intratympanically 
Confocal microscope images revealed preservation of outer (OHC) and inner hair cells 
(IHC) in all specimens (Fig. 4) with integrity of cilia (Fig. 5).  
3.2.2. Group B We found a decrease in threshold levels for both ears. Differences 
between pre- and post-treatment thresholds in group B were smaller in the right ear 
(lutein) compared to the left ear (saline solution) (Fig. 6), but not statistically significant 
(p > 0.05). Severe structural changes and scarce OHC were observed, with no damage 
to the IHC. The percentage of missed OHC was similar both in the study ear (lutein) 
and the control ear (saline solution). Cells undergoing apoptosis showed morphological 
changes such as chromatin condensation and nuclear pycknosis or fragmentation. Hair 
cell damage difference between ears was not statistically significant (p > 0.05).  
3.2.3. Lutein quantification Lutein was detected in only one sample from a rat 
euthanised 30 min after lutein intratympanic administration. The method employed in 
this study was not appropriate to determine exact amounts of lutein present in the 
cochlear fluid due to the low concentrations present.  
4. Discussion  
In this study, we evaluated dose-dependent effects of lutein on HEI-OC1 cell line 
challenged with cisplatin. Lutein shows a dose-dependent cytoprotective effect in 
vitro. A protective effect was found in an in vivo animal model of cisplatin ototoxicity 
(albino Wistar rat), without reaching statistical significance. Although a great diversity 
of pharmacological strategies have been explored to protect cochlear structures 
against cisplatin effects without interfering with its antitumoral activity, none is 
currently approved to prevent cisplatin ototoxicity. In view of the role of ROS as the 
principal element in apoptosis- induction mechanisms after cisplatin administration, 
antioxidants have been proposed as good candidates to protect inner ear during 
cisplatin treatment. In a recent literature review on the efficacy of molecules tested in 
animal cisplatin ototoxicity models (Roldán- Fidalgo et al., 2015), 40 out of 64 
candidate substances were antioxidants, and antioxidant substances achieved 
functional otoprotection in a higher percentage of studies than non-antioxidant 
agents. A systematic review of literature is necessary to further analyse these findings, 
but it is remarkable how often antioxidant molecules have been tested as potential 
otoprotectors. Lutein is a carotenoid with antioxidant, anticarcinogenic and anti-
inflammatory properties (Vijayapadma et al., 2014). In the field of ophthalmological 
diseases, it is well known that lutein and zeaxanthin are present in the macula and lens 
of the human eye (Landrum and Bone, 2001; Olmedilla-Alonso et al., 2014). These 
carotenoids have a dual ocular function, contributing to the filtration of ultraviolet rays 
and exerting an antioxidant function against ROS produced by this radiation. 
Observational studies have shown an inverse relationship between the intake of lutein 
and the presence of age-related macular degeneration (Mares-Perlman et al., 2001), 
cataracts (Olmedilla et al., 2003; Gale et al., 2014; Liu et al., 2014) and retinitis 
pigmentosa (Beatty et al., 2000). Lutein antioxidant activity has been biochemically 
reported in in vitro studies using human erythrocytes (Vijayapadma et al., 2014) and 
human retinal pigment epithelial cells (ARPE-19). Studies on the effects of lutein in 
oxidative stress parameters in lab animals and cell cultures have shown that lutein 
might act as a scavenger and also inducing the expression of genes related to a better 
antioxidant response (Serpeloni et al., 2014; Aimjongjun et al., 2013) 
There are several similarities between the inner ear and the retina. Photoreceptor and 
retinal pigment epithelial (RPE) cells and hair cells of the inner ear have a very similar 
structure. They all present regions of amplified plasma membrane (the apical microvilli 
in RPE cells, the disk membranes in photoreceptor cells, and the stereocilia in hair 
cells) (Tombran-Tink and Barnstable, 2007). There is a polarised organisation within 
the plane of an epithelium cell of both organs. Planar polarity is essential for nervous 
system development and function, mutations in planar polarity genes result in several 
defects such as blindness, hearing loss or vestibular disorders. Most variants in both 
organs have the same molecular weights, which portends to similar functional roles for 
these proteins in the cochlea and the retina. Recent biochemical analysis documents a 
number of protein variants for VLGR1, cadherin 23, and protocadherin 15 in the 
cochlea and the retina (Lagziel et al., 2009; Zallocchi et al., 2012). Due to the 
involvement of ROS generation and inflammation mediators in cisplatin toxicity 
(Casares et al., 2012), and these common characteristics, there is a strong rationale for 
testing lutein as a protective agent against cisplatin-induced damage due to its 
antioxidant and anti-inflammatory activity. Previous in vivo studies on lutein employ 
systemic administra- tion routes. Most articles published show that administration of 
lutein in the diet or as a dietary supplement is safe and effective. However, there are 
concerns in the scientific community about the possibility that systemic administration 
of a protective molecule could interference with the antitumoral effect of cisplatin. 
These concerns have limited the clinical use of protective agents (Blakley et al., 2002). 
Intratympanic administration of an agent-containing solution allows for diffusion 
across the round window membrane into the inner ear, where it can exert its effects. 
This administration route has been shown to provide higher levels of corticosteroids 
within the inner ear when compared to systemic routes (Parnes et al., 1999). 
Intratympanic administration route is a simple and safe method currently employed in 
the treatment of patients suffering from sudden sensorineural hearing loss and 
inmuno-mediated hearing loss, and we therefore consider it an adequate 
administration route for testing protective agents in animal ototoxicity studies. The 
potential interference of systemical lutein administration on the cisplatin effect could 
compromise its antitumoral action. Therefore we have chosen the intratympanic 
administration route in the present study This is the first study that evaluates the 
effect of intratympanic administration of lutein in an animal model of cisplatin 
ototoxicity. As a result, no references have been found concerning the ideal dose to be 
used by this administration route. The employed concentrations in other models are 
variable, ranging from 0.1 mg/mL employed in a model of ear inflammation in a rat 
model (Horvath et al., 2012) to 15 mg per day in 1 mg/mL injected locally in a rat 
model of blue light eye exposure (Wang et al., 2008). Although it is known that the 
HEI-OC1 line is very sensitive to ototoxicity, the data for lutein toxicity using 
concentrations of 100 mM indicate that the administration of this drug in high 
concentrations can damage the inner ear cells. The administration of lutein with 
cisplatin did not result in an enhancement of its ototoxic effect. Although hearing 
thresholds in the ear treated with lutein were better than in the saline-treated ear, no 
statistically significant differences were obtained. Protective effects of lutein in our in 
vitro study but not in the in vivo study could be due to several reasons: 1. Lutein is not 
able to protect the organ of Corti of the Wistar rat against the toxic effects of cisplatin. 
2. The amount of lutein administrated in the middle ear of the Wistar rat was not large 
enough to exert its protective action. In fact, lutein was only detected in a sample of 
cochlear fluid, obtained 30 min after intratympanic administration. Some factors that 
may explain this fact are: a) The total amount of solution available within the middle 
ear is limited by the volume of the middle ear in the rat, which is of 0.03 mL in young 
individuals. b) Insufficient dilution of lutein in DMSO. c) Loss of the agent through the 
Eustachian tube or by diffusion to the cochlear aqueduct d) Limitations to the diffusion 
of lutein through the round window membrane due to its high molecular weight 
(although large molecules can diffuse the round window membrane by pinocytosis) 
(Juhn et al., 1989). e) Early diffusion of lutein into the hair cells. f) A low detection 
capability of the device due to the small amount of cochlear fluid. 
DMSO employed to dissolve lutein is a diffusion facilitating agent, but the fact that 
lutein was detected only in one of the perilymph samples suggests that transport of 
the molecule to the perilymphatic spaces could be impaired by some of the aforemen-
tioned factors. Potential for improvement may lie in enhancing the solubility of lutein, 
in using other diffusion facilitators, using another animal model with a larger middle 
ear and in increasing lutein stability and diffusion using nanotechnology. A more 
detailed knowledge of the cisplatin molecular processes might clarify whether certain 
antioxidants are more effective in modulating specific pathways. Testing systemic 
routes of administration for lutein warrant further research as several studies have 
shown that chemo-protection route and timing of administration can be adapted to 
maintain CDDP antitumor efficacy while protecting against chemotherapy toxic side 
effects (Neuwelt et al., 2006; Dickey et al., 2005).  
5. Conclusions  
To the best of our knowledge, the present paper is the first study to evaluate the effect 
of intratympanic lutein administration in vitro and in vivo. Although lutein achieved 
otoprotection in HEI-OC1 cells challenged with cisplatin, the present study did not 
show any protective effect against cisplatin toxicity in an in vivo model Wistar rat with 
the dose and the administration route employed.  
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